| The use of major analgesics in patients with renal dysfunction P Niscola, L Scaramucci, G Vischini, M Giovannini, M Ferrannini, P Massa, ... Current drug targets 11 (6), 752-758, 2010 | 96 | 2010 |
| IgA nephropathy and infections C Rollino, G Vischini, R Coppo Journal of nephrology 29, 463-468, 2016 | 93 | 2016 |
| Heparanase: a potential new factor involved in the renal epithelial mesenchymal transition (EMT) induced by ischemia/reperfusion (I/R) injury V Masola, G Zaza, G Gambaro, M Onisto, G Bellin, G Vischini, I Khamaysi, ... PloS one 11 (7), e0160074, 2016 | 49 | 2016 |
| Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury V Masola, G Zaza, G Bellin, L Dall'Olmo, S Granata, G Vischini, ... The FASEB Journal 32 (2), 742-756, 2018 | 46 | 2018 |
| Pain management in multiple myeloma P Niscola, L Scaramucci, C Romani, M Giovannini, A Tendas, G Brunetti, ... Expert review of anticancer therapy 10 (3), 415-425, 2010 | 39 | 2010 |
| Increased plasma levels of tacrolimus after ingestion of green tea G Vischini, P Niscola, A Stefoni, F Farneti American Journal of Kidney Diseases 58 (2), 329, 2011 | 35 | 2011 |
| Rheopheresis in vascular diseases M Ferrannini, G Vischini, E Staffolani, F Scaccia, N Miani, MC Parravano, ... The International journal of artificial organs 30 (10), 923-929, 2007 | 24 | 2007 |
| Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury V Masola, G Bellin, G Vischini, L Dall'Olmo, S Granata, G Gambaro, ... Oncotarget 9 (90), 36185, 2018 | 22 | 2018 |
| A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy A Milillo, F La Carpia, S Costanzi, V D'urbano, M Martini, P Lanuti, ... European Journal of Human Genetics 23 (12), 1673-1678, 2015 | 21 | 2015 |
| Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications V L'Imperio, G Vischini, F Pagni, PM Ferraro Annals of the Rheumatic Diseases 81 (6), e95-e95, 2022 | 19 | 2022 |
| Proteinuria is a late-onset adverse event in patients treated with cabozantinib V Cappagli, D Moriconi, AG Bonadio, D Giannese, G La Manna, MF Egidi, ... Journal of Endocrinological Investigation 44, 95-103, 2021 | 16 | 2021 |
| MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy. MF L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S ... Proteomics Clin Appl., 2018 | 14* | 2018 |
| Management of hematological malignancies in patients affected by renal failure P Niscola, G Vischini, A Tendas, L Scaramucci, M Giovannini, ... Expert review of anticancer therapy 11 (3), 415-432, 2011 | 14 | 2011 |
| Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura A Milillo, C Molinario, S Costanzi, G Vischini, F La Carpia, F La Greca, ... Journal of nephrology 31 (5), 731-741, 2018 | 13 | 2018 |
| Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report. G Vischini, L Cudillo, M Ferrannini, N Di Daniele, R Cerretti, W Arcese Journal of Nephrology 22 (1), 160-163, 2009 | 12 | 2009 |
| Rituximab in membranous nephropathy after haematopoietic stem cell transplantation. M Ferrannini, G Vischini, N Di Daniele Nephrology, Dialysis, Transplantation: Official Publication of the European …, 2008 | 9 | 2008 |
| Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience A De Giglio, V Grandinetti, M Aprile, G Borelli, A Campus, ALC Chiocchini, ... Lung Cancer 174, 91-96, 2022 | 8 | 2022 |
| Successful pregnancy in a uremic patient treated with single needle hemodialysis M Ferrannini, G Vischini, N Miani, E Staffolani, N Di Daniele The International Journal of Artificial Organs 30 (12), 1122-1125, 2007 | 8 | 2007 |
| Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies L Petricca, MR Gigante, A Paglionico, S Costanzi, G Vischini, C Di Mario, ... Frontiers in Medicine 7, 553075, 2020 | 7 | 2020 |
| A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome G Vischini, ME Kapp, FC Wheeler, L Hopp, AB Fogo Human Pathology 81, 229-234, 2018 | 6 | 2018 |
